They found that a higher Ki-67 to tumor burden ratio significantly predicts a better objective response and survival in the test cohort but had borderline significance in the validation cohort.
← all excerpts
Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy.
1
—
—